BRIEF-US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa

Reuters

29 Apr

BRIEF-US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa

April 29 (Reuters) - Abeona Therapeutics Inc ABEO.O:

U.S. FDA APPROVES ZEVASKYN™ (PRADEMAGENE ZAMIKERACEL), THE FIRST AND ONLY CELL-BASED GENE THERAPY FOR PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)
ABEONA THERAPEUTICS INC - ZEVASKYN TO BE AVAILABLE THROUGH QUALIFIED TREATMENT CENTERS IN 3Q 2025

Source text: ID:nGNXbzwPMP

Further company coverage: ABEO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531207459"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531207459\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531207459?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 18:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531207459","market":"nz","top_or_hot":-1,"title":"BRIEF-US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa</title></head><body><p><span>April 29 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ABEO\">Abeona Therapeutics Inc</a> <span>ABEO.O</span>:</p><ul><li><p>U.S. FDA APPROVES ZEVASKYN™ (PRADEMAGENE ZAMIKERACEL), THE FIRST AND ONLY CELL-BASED GENE THERAPY FOR PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)</p></li><li><p>ABEONA THERAPEUTICS INC - ZEVASKYN TO BE AVAILABLE THROUGH QUALIFIED TREATMENT CENTERS IN 3Q 2025</p></li></ul><p>Source text: <span>ID:nGNXbzwPMP</span></p><p>Further company coverage: <span>ABEO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-29 18:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa</title></head><body><p><span>April 29 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ABEO\">Abeona Therapeutics Inc</a> <span>ABEO.O</span>:</p><ul><li><p>U.S. FDA APPROVES ZEVASKYN™ (PRADEMAGENE ZAMIKERACEL), THE FIRST AND ONLY CELL-BASED GENE THERAPY FOR PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)</p></li><li><p>ABEONA THERAPEUTICS INC - ZEVASKYN TO BE AVAILABLE THROUGH QUALIFIED TREATMENT CENTERS IN 3Q 2025</p></li></ul><p>Source text: <span>ID:nGNXbzwPMP</span></p><p>Further company coverage: <span>ABEO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABEO","symbol_name":"Abeona Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA6B6F7B:1","article_id":"2531207459","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531207459","pubTimestamp":1745921597,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis BullosaApril 29 (Reuters) - Abeona Therapeutics Inc ABEO.O:U.S. FDA APPROVES","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABEO":"Abeona Therapeutics Inc","BK4139":"生物科技"},"translate_title":"简介-美国FDA批准ZEVASKYN，首个也是唯一一个针对隐性营养不良性大疱性表皮松解症患者的基于细胞的基因疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABEO":0.9},"content_text":"BRIEF-US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis BullosaApril 29 (Reuters) - Abeona Therapeutics Inc ABEO.O:U.S. FDA APPROVES ZEVASKYN™ (PRADEMAGENE ZAMIKERACEL), THE FIRST AND ONLY CELL-BASED GENE THERAPY FOR PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)ABEONA THERAPEUTICS INC - ZEVASKYN TO BE AVAILABLE THROUGH QUALIFIED TREATMENT CENTERS IN 3Q 2025Source text: ID:nGNXbzwPMPFurther company coverage: ABEO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}